Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -1.7 million
▲ 5% vs 2024
Profit
Caution€ -14.8 million
▼ 73% vs 2024
Debts
Low€ 1.9 million
▼ 6% vs 2024
AUGUSTINE THERAPEUTICS from Leuven, company number BE0722705230, closed financial year 2025 with a result of € -14.8 million after tax. For that financial year AUGUSTINE THERAPEUTICS recorded a gross margin of € -1.7 million and equity of € 29 million. Compared with financial year 2024, the result moved from € -8.6 million to € -14.8 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
What happened at AUGUSTINE THERAPEUTICS?
What happened at AUGUSTINE THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Participatiemaatschappij Vlaanderen (PMV) stepped down as director. NBB
- Gerhard Koenig stepped down as director. NBB
- Pascale Florence Geneviève Witz stepped down as director. NBB
- Emmanuelle Coutanceau stepped down as director. NBB
- Mahieddine El Mahdi Ainouche stepped down as director. NBB
- Clara Campàs Moya stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 14.8 million. Source: NBB ↗
- Pascale Florence Geneviève Witz became a director. NBB
In short
From € 1.8 million loss in 2021 to € 14.8 million loss in 2025.
A new publication or filing at AUGUSTINE THERAPEUTICS? We notify you, reason included.
Follow AUGUSTINE THERAPEUTICSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Augustine Therapeutics Denmark ApS itself.
Directors
According to the 2025 annual accounts
Participatiemaatschappij Vlaanderen (PMV)
Director · represented by Bart De Taeye
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE +141 more
since 2025 · until 2031
Gerhard Koenig
Director
since 2025 · until 2031
Alain Huriez
Director
since 2024 · until 2025
Pascale Florence Geneviève Witz
Director
since 2025 · until 2031
Emmanuelle Coutanceau
Director
since 2025 · until 2031
Ward Capoen
Director
since 2024 · until 2025
Mahieddine El Mahdi Ainouche
Director
since 2025 · until 2031
Sylvain Celanire
Managing director
since 2024 · until 2025
Clara Campàs Moya
Director
since 2025 · until 2031
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics same network
€ -528,262 gross margin · 2025
Montis Biosciences
€ -2.1 million gross margin · 2025
+6 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Domain
Domain
augustinetx.com
Registered
2019-12-12
Registrar
Combell NV
Expires
2026-12-12
Website info
Features
Security
Details
- Company number
- 0722.705.230
- VAT number
- BE 0722.705.230
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- AUGUSTINE THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 March 2019
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- augustinetx.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied